Actively Recruiting
Comparing Fixed Duration versus Continuous Anti-CD38 Antibody Therapy with Lenalidomide and Dexamethasone in Older Adults with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Led by Canadian Cancer Trials Group · Updated on 2026-10-14
570
Participants Needed
31
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment strategies for transplant-ineligible older adults with newly diagnosed multiple myeloma. The study compares continuous use of anti-CD38 antibodies daratumumab or isatuximab alongside lenalidomide and dexamethasone against a fixed duration approach where these antibodies are stopped after about a year and a half. The goal is to determine if a shorter antibody treatment works as well as continuous therapy. Participants will be randomly assigned to one of two groups. One group will continue standard care with ongoing daratumumab or isatuximab combined with lenalidomide and dexamethasone. The other group will stop the antibody injections after completing 18-20 cycles but continue the other medications indefinitely as long as they benefit. The study includes two treatment arms one with lenalidomide and dexamethasone alone, and the other with those drugs plus daratumumab or isatuximab. During the trial, participants will undergo regular assessments including measurements of disease progression, survival, response rates, side effects, quality of life, and economic factors over a period of approximately 9 years. Researchers will monitor the safety and effectiveness of the treatments and gather data through questionnaires and clinical evaluations. Participants will remain on treatment as long as they continue to benefit and will be followed closely throughout the study duration.
CONDITIONS
Brief Title
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Research Team
A
Annette Hay
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here